Please login to the form below

Not currently logged in
Email:
Password:

Amicus

This page shows the latest Amicus news and features for those working in and with pharma, biotech and healthcare.

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

Narrowly missing first place, but still achieving a highly commended status on the night was Amicus Therapeutics UK for its work on rare diseases. ... Judges said: “Amicus did a very good job for a small outfit in the start-up phase and they showed an

Latest news

  • Amicus Therapeutics launches Fabry treatment Galafold in Italy Amicus Therapeutics launches Fabry treatment Galafold in Italy

    Amicus Therapeutics launches Fabry treatment Galafold in Italy. Follows publication of Ministry of Health's reimbursement guidelines. ... US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    Amicus gets NICE green light for Fabry drug. Oral therapy alternative Galafold approved for routine NHS use. ... The National Institute of Health and Care Excellence has given its blessing to Amicus' oral therapy for Fabry disease, a rare genetic disorder

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    SMC approves Opdivo combo as first-line skin cancer treatment. Also backs Gilead’ s Epclusa, Baxalta’ s Oncaspar, AZ’ s Lynparza and Amicus’ Galafold. ... Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    The committee gave Amicus Therapeutics' genetic disorder treatment the provisional green light, bringing UK patients one step closer to an orally administered alternative to the standard fortnightly injections. ... The regulator has agreed a confidential

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    Amicus Therapeutics got a green light from the CHMP for Galafold (migalastat) as the first oral treatment for Fabry disease, which is caused by a deficiency in alpha-galactosidase A. ... The positive opinion marks a turnaround for migalastat, which had

More from news
Approximately 6 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Secondly, Amicus announced the purchase of Callidus Biopharma for $15m in stock and up to $115m in milestones. ... The deal gives Amicus access to Callidus' late-stage enzyme replacement therapy for Pompe disease.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    152. Calidus / Amicus. Acquisition. Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics